RECURRENT GLIOBLASTOMA

This early-stage trial tests an experimental drug called CT-179 in people with glioblastoma, an aggressive brain cancer. The study has two parts: one for patients whose cancer has returned, and another for newly diagnosed patients who will also receive radiation therapy. The main…

This early-phase trial tests a new way to treat recurrent glioblastoma, an aggressive brain cancer. Tiny radioactive beads called SIR-Spheres® are injected into the blood vessels feeding the tumour to deliver radiation directly inside it. The study aims to see if this approach is…

This early-stage study tests a new drug called BRiTE for safety in 18 adults with a specific type of glioblastoma (a fast-growing brain cancer). The drug is given as a continuous IV drip over 4 days each month. Only patients whose tumors have a specific genetic marker (EGFRvIII) …

This study tests a new approach for recurrent glioblastoma, an aggressive brain cancer. It combines a minimally invasive laser that heats and destroys tumor tissue (LiTT) with an immunotherapy drug called cemiplimab, which helps the immune system attack cancer cells. About 99 par…

This early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an …